The BET bromodomain inhibitor CPI203 improves lenalidomide activity in in vitro and in vivo models of multiple myeloma by synergistic blockade of Ikaros and c-Myc signaling

GSE87403

Homo sapiens

12 Downloadable Samples

Affymetrix Human Genome U219 Array (hgu219)

Submitter Supplied Information

Description

Multiple myeloma (MM) cells were treated with the BET inhibitor CPI203 alone and in combination with lenalidomide plus dexamethasone in vitro and in vivo (mouse xenograft).

PubMed ID

28751557

Publication Title

The BET bromodomain inhibitor CPI203 improves lenalidomide and dexamethasone activity in <i>in vitro</i> and <i>in vivo</i> models of multiple myeloma by blockade of Ikaros and MYC signaling.

Total Samples

Submitter’s Institution

IDIBAPS

Authors

Díaz T, Rodríguez V, Lozano E, Mena MP, Calderón M, Rosiñol L, Martínez A, Tovar N, Pérez-Galán P, Bladé J, Roué G, de Larrea CF

Source Repository

Gene Expression Omnibus (GEO)

No rows found